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Abstract
Existing approaches that quantify cytotoxic T cell responses rely on bulk or surrogate measurements which impede the
direct identification of single activated T cells of interest. Single cell microscopy or flow cytometry methodologies typically
rely on fluorescent labeling, which limits applicability to primary cells such as human derived T lymphocytes. Here, we
introduce a quantitative method to track single T lymphocyte mediated cytotoxic events within a mixed population of cells
using live cell interferometry (LCI), a label-free microscopy technique that maintains cell viability. LCI quantifies the mass
distribution within individual cells by measuring the phase shift caused by the interaction of light with intracellular biomass.
Using LCI, we imaged cytotoxic T cells killing cognate target cells. In addition to a characteristic target cell mass decrease of
20–60% over 1–4 h following attack by a T cell, there was a significant 4-fold increase in T cell mass accumulation rate at the
start of the cytotoxic event and a 2–3 fold increase in T cell mass relative to the mass of unresponsive T cells. Direct, label-
free measurement of CD8+ T and target cell mass changes provides a kinetic, quantitative assessment of T cell activation
and a relatively rapid approach to identify specific, activated patient-derived T cells for applications in cancer
immunotherapy.
Citation: Zangle TA, Burnes D, Mathis C, Witte ON, Teitell MA (2013) Quantifying Biomass Changes of Single CD8+ T Cells during Antigen Specific
Cytotoxicity. PLoS ONE 8(7): e68916. doi:10.1371/journal.pone.0068916
Editor: Clive M. Gray, University of Cape Town, South Africa
Received January 25, 2013; Accepted June 3, 2013; Published July 23, 2013
Copyright:  2013 Zangle et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a UC Discovery/Abraxis Bioscience Biotechnology Award (Bio07-10663, M.A.T., www.ucop.edu/research-grants-program),
the Broad Stem Cell Research Center at UCLA (M.A.T., www.stemcell.ucla.edu), a Translational Acceleration Grant from the Caltech-UCLA Joint Center for
Translational Medicine (M.A.T., www.jctm.caltech.edu), and training grants from the NIH (T32CA009120 and K25CA157940, T.A.Z.). D.L.B is supported by the
Natural Sciences and Engineering Research Council of Canada Post Graduate Scholarship (PGS-D3 388938-2010). O.N.W. is an Investigator of the Howard Hughes
Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: T.A.Z., D.B, O.N.W., and M.A.T. have submitted a patent disclosure to the UCLA Office of Intellectual Property Administration (OIPA)
regarding the work described in this paper. Also, a patent application on the LCI technology has been filed by UCLA OIPA with M.A.T. listed as a co-inventor. US
patent application names and number #1: Michael A. Teitell, Jason C. Reed, and James K. Gimzewski; Optical Cytometry, US Serial Number 12/436,702 US
provisional patent application names and number#2: Michael A. Teitell and Jason C. Reed; Rapid, Massively Parallel Single-Cell Drug Response Measurements Via
Live Cell Interferometry, US Serial Number 61/514,353. There are no further patents, products in development or marketed products to declare. This does not alter
the authors’ adherence to all the PLOS One policies on sharing data and materials.
* E-mail: owenwitte@mednet.ucla.edu (ONW); mteitell@ucla.edu (MAT)
. These authors contributed equally to this work.
Introduction
CD8+ T lymphocyte mediated cytotoxicity is a critical
component of the adaptive immune response against viruses and
cancers, and is also implicated in autoimmunity [1,2]. T cell
mediated cytotoxicity is typically measured by target cell death or
surrogate markers of effector cell cytotoxic capacity. The canonical
assays are the 51Cr release assay and ELISPOT, both of which
provide bulk measurements of whole lymphocyte population or
sub-population responses [3,4]. The introduction of peptide-MHC
tetramers and microfluidic platforms has allowed for surrogate
measures of cytotoxicity through analysis of T cell antigen
specificity and cytokine secretion [3,5,6]. Directly tracking T
lymphocyte mediated cytotoxicity at the single cell level is
advantageous for analyzing cytotoxic T cells (CTLs) within a
mixed population, which is of particular relevance in assessing T
cell recognition against cancer cells. Viable CTLs can potentially
be cultured and expanded further, or the corresponding T cell
receptors (TCRs) bearing optimal specificity toward immunogenic
peptides can be molecularly cloned for utilization in a clinical
setting [7].
Optical microscopy allows for direct identification and tracking
of CTLs in the full context of target cell recognition and killing.
Optical imaging methods such as epifluorescence, confocal
microscopy, total internal reflection fluorescence and two photon
laser scanning microscopy have been explored for the study of
lymphocyte activation, but typically require antibody or conjugat-
ed protein labeling to track and quantify cells [8,9]. This limits
applicability to studies of T lymphocytes due to transduction
inefficiencies associated with diverse phenotypes as well as
progressive differentiation towards exhaustion or senescence
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during in vitro culture, as is required for typical fluorescence
labeling techniques [10,11]. Live cell interferometry (LCI) is a
label-free optical microscopy technique which measures whole cell
responses. LCI uses a Michelson-type interferometer to compare
the optical thickness of living cells in a sample chamber to the
optical thickness of fluid in a reference chamber in order to
quantify the optical thickness difference between a cell and its
surrounding media [12,13]. The optical thickness difference due to
the interaction of light with cellular biomass is linearly propor-
tional to the material density of a cell [14]. Based on this
interaction, cell mass can be related to the measured phase
retardation of light passing through each cell with 2% precision in
total cell mass [12–14]. Practically, LCI yields measurements of
mass and mass accumulation or loss rates of 100–400 cells
simultaneously per imaging location within 1–5 h of imaging [12].
With automated measurements every 2–5 minutes to allow for
accurate tracking and mass determination during cytotoxic events
at 20–50 imaging locations, this technique can quantify the mass
of 2,000 to 20,000 cells.
Our approach directly tracks T lymphocyte mediated cytotox-
icity at the single cell level without labeling by quantifying the mass
of individual CTLs and their cognate target cells. Single cytotoxic
events are identified and evaluated over time within a mixed
population, using the mass data to confirm individual T cell
mediated cytotoxicity events. As a proof of concept, we
demonstrate tracking of up to 2,000 individual CTLs with
specificity toward Melanocytic Antigen Recognized by T lympho-
cytes (MART1) responding against human leukocyte antigen
(HLA) matched MART1+ target cells [15]. Target cells are
imaged by the LCI to establish a base-line mass accumulation rate.
CTLs are then plated onto the target cells and individual cytotoxic
events are identified as a characteristic decrease in target cell mass
following contact with a corresponding T cell.
It is well established that T cells increase in size during
activation [16]. This previously observed increase in size may
result from a change in solute concentration or osmolality within
the cell as opposed to an increase in biomass [17]. Using our
approach we determine that the size increase in CTLs responding
to cognate target cells is due to an increase in biomass and that
biomass measurements provide robust identification of activated T
cells. The capacity to measure the mass of a single CTL opens
several potential downstream applications including T cell
biological studies pertaining to metabolic or differentiation states
in addition to the analysis of CTLs for potential use in adoptive
immunotherapy protocols.
Materials and Methods
Cell Lines & PBMCs
M202, M207, [18] PC-3, PG13, and 293T cells (ATCC) were
routinely maintained at 37uC in 8% CO2, using either DMEM or
RPMI1640 Media supplemented with 5% FBS, 100 U/mL
penicillin, 100 mg/mL streptomycin and 2 mmol/l-glutamine.
HLA A2.1+ PBMCs derived from anonymized healthy donors
were obtained from the Center for AIDS Research Virology Core
Lab at UCLA and frozen following collection. Thawed PBMCs
were revived in complete medium (CM) plus anti-CD3/2/28
beads for 4 d prior to retroviral infection. CM consisted of AIM-V
media (Invitrogen, USA) supplemented with 25 mmol/L HEPES,
5.561025 mol/L b-mercaptoethanol and 300 IU/mL IL-2.
PBMCs were in culture for a total of 7–10 d prior to all imaging
experiments. Cells were maintained in complete media on the LCI
imaging platform.
Generation of MART1 specific CD8+ T cells
F5 retrovirus was collected from PG13 cells modified to produce
retroviral vector consisting of the F5 TCR with specificity toward
the MART1 ELAGIGLTV peptide fragment, which is expressed
by the M202 and M207 cell lines used in cytotoxicity experiments.
Briefly, 293T cells were transfected with the packaging vector
pCL-Eco and the MSCV-based retroviral vector RV-MSCV-
F5MART1 TCR. Resulting supernatants were used to transduce
the murine PG13 retrovirus packaging cell line for Gibbon ape
leukemia virus (GaLV) envelope-pseudotype generation. PBMCs
were infected with the retrovirus containing PG13 supernatant in
the presence of Retronectin (Takara, Japan) according to the
manufacturer’s protocol. 48–72 h after infection the cells were
stained with MART1 specific tetramer (Beckman Coulter, USA)
and analyzed by flow cytometry (FACSCanto, BD Biosciences,
USA). CD8+ T cells were isolated by negative enrichment (Stem
Cell Technologies, USA) and the enrichment efficiency was
verified by flow cytometry.
IFNg measurement by flow cytometry
To verify the functional specificity of DMF5 transduced CD8+
T cells, a total of 16105 T cells were co-cultured with 16105 target
cells (M202 or M207) in a 96-well flat plate with 200 ml of
complete medium in a humidified incubator at 37uC and 8% CO2
for 18 h. The concentration of IFN-gamma in the supernatant was
determined by flow cytometry using the Human IFNg FlowCy-
tomix Simplex kit following the manufacturer’s protocol
(eBioscience, USA cat# BMS8228FF).
LCI mass measurements
Target cells were plated onto 20 mm620 mm silicon slides
treated with a 0.01% solution of poly-l-lysine (Sigma) at a density
of approximately 2.56104 cells/cm2 and allowed to grow in a cell
culture incubator for 48 h prior to the start of imaging
experiments. A silicon slide with attached target cells was placed
into a custom-built, temperature and CO2 controlled perfusion-
based live cell imaging chamber and imaged for approximately
1.5 h before the addition of T cells. The T cell-target cell co-
culture was imaged continuously for 18 h. 30 imaging locations
were chosen based on suitable density of target cells on the silicon
substrate and images collected approximately once every 3 to 4
min. Imaging was performed using a modified GT-X8 optical
profiler (Bruker) at 206magnification (numerical aperture 0.28)
with a 0.55x demagnifying lens to increase field of view while
preserving resolution. Interference fringes were generated using a
Michelson-type interferometer consisting of a beam splitter,
reference mirror and a reference fluid chamber which compen-
sates for the optical path length through the sample chamber.
Images were acquired using the phase-shifting interferometry (PSI)
method with illumination from a 530 nm fiber-coupled LED
(Thorlabs). Intensity images represent the average intensity of the
image without the interference fringes necessary for Michelson
phase imaging.
Phase Unwrapping
To remove the integer-wavelength phase ambiguities inherent
in quantitative phase imaging [19], we performed phase unwrap-
ping using a custom script implemented in Matlab (Mathworks).
First, we performed unwrapping based on Flynn’s minimum
discontinuity method [19]. Next, a training dataset was construct-
ed by manually applying single wavelength corrections to
approximately 200 sub-images of the phase data, selected for the
appearance of target and T cells of interest. This training dataset
Mass Changes During CTL Target Cell Killing
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was used in a linear discriminant analysis (LDA) to identify pixels
which lie on the boundary of phase-wrapped regions, based on 16
sets of image statistics, including the raw image itself, the
computed intensity image, and the results of various edge-finding
filters applied to the wrapped phase image. LDA was followed by
genetic optimization to refine the LDA results and watershed
algorithm thresholds used in determining the boundaries of phase-
wrapped regions. Regions within the boundaries determined by
the watershed algorithm applied to the final LDA result were
shifted (corrected) by a phase shift of one wavelength and median
filtered with a kernel size of 3.
Mass Tracking
Single cell mass measurements were performed using a custom
script implemented in Matlab (Mathworks). Briefly, phase-
corrected images were Gaussian low pass-filtered before image
segmentation based on Otsu thresholding. Finally, objects
identified by image segmentation were tracked using the particle
tracking code adapted for Matlab by Daniel Blair and Eric
Dufresne, based on the particle tracking algorithm by Grier et al.
[20]. Cell area was determined using a local adaptive threshold
based on a 200 pixel neighborhood in the quantitative phase
image.
Statistics
Statistical analysis was performed using a two-tailed Welch’s
Student T test with unequal variances and sample sizes.
Results
LCI for quantitative imaging of T cell mediated
cytotoxicity
We developed a model system for analyzing cytotoxicity events
by establishing the antigen specificity of healthy human donor
CD8+ enriched lymphocytes against HLA matched target cell
lines. Peripheral blood mononuclear cells (PBMCs) were trans-
duced with an F5 anti-MART1 TCR, which is a high affinity
TCR with specificity toward MART1 [15]. Target cells expressing
MART1 and antigen-defined CD8+ enriched T cells were co-
cultured in a live-cell observation chamber on the LCI stage and
imaged for a period of 18 h. (Figure 1A). The observation
chamber was temperature controlled with pH maintained by
continuous perfusion of media equilibrated at 8% CO2. Following
image collection, the light phase shift data was corrected for phase
wrapping errors which are caused by the integer wavelength
ambiguity inherent in quantitative phase imaging [19]. The result
is a map of phase shifts across each cell that can be converted into
a map of local dry mass density (Figure 1B). The total dry mass of
a cell is quantified as the sum of the local densities [12,14,21]:
m~k
ð
wldA, ð1Þ
where m is cell dry mass, Ql is the measured phase shift, k is the
mass conversion factor, and A is projected area. The mass
conversion factor [21,22], which is a measure of the change in
density per unit change in refractive index (Dr/Dn), is taken as
k=5.56 pg/mm3 [14]. This parameter, k, is measured as a change
in refractive index relative to the refractive index of water,
Therefore, the cell mass measured in this manner is the cell dry
mass, or the mass of everything within the cell other than water.
With this equation, the measured dry mass of the activated T cell
in Figure 1B is 240 pg, the target cell mass is 840 pg and the
unactivated T cells have an average dry mass of 65 pg.
Antigen-specific T cells and maintenance of viability on
the imaging platform
To generate antigen-defined CTLs, we infected HLA A2.1+
healthy donor PBMCs with the F5 TCR by retroviral transduction
and enriched for CD8+ cells by magnetic separation to remove
magnetically labeled non-CD8+ cells (Figure 2A–B). Although
CD8+ T cells have endogenous TCRs, ectopic expression of the
Figure 1. LCI measures mass of T and target cells. (A) Workflow for T cell mass measurement experiments. Donor peripheral blood
mononuclear cells (PBMCs) are transduced with the MART1 specific, F5 TCR and enriched for CD8+ T cells. A subset of these T cells are analyzed by
flow cytometry to confirm a transduction efficiency of greater than 50%. The remaining cells are imaged on the LCI with MART1 expressing, HLA-
matched (or mismatched control) M202 target cells. (B) Sample LCI data showing the phase shift and mass distributions in an activated, F5-
transduced CD8+ T cell, several unresponsive T cells, and a dying target cell.
doi:10.1371/journal.pone.0068916.g001
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F5 anti-MART1 TCR results in overexpression of the exogenous
alpha and beta chains to allow for preferential pairing and surface
expression. The majority of isolated cells were CD8+ with 75%
expressing the F5 TCR on the surface, as determined by MART1
peptide tetramer stains prior to imaging. We measured interferon
gamma (IFNg) accumulation in the supernatant following an 18 h
co-culture period to verify that F5 redirected CD8+ T cells were
specific for the cognate target cells. Results of a bead-based
immunoassay analyzed by flow cytometry indicated a significant,
3.5-fold higher, IFNg release from F5 transduced CTLs upon co-
culture with HLA-matched MART1+ M202 target cells as
compared to co-culture with an HLA-mismatched control cell
line (Figure 2C).
Target cells were imaged in standard culture media for 1.5 h
prior to the start of each experiment to confirm the live cell culture
imaging platform maintains viability of target cells in the absence
of CTLs. M202 target cells showed a positive mass accumulation
rate, indicating a healthy population and the maintenance of cell
viability. (Figure 2D–E and Figure S1B). Control experiments
demonstrated maintenance of both T and target cell viability
during extended imaging periods (Figure S1 and Figure S2).
Mass decrease of killed target cells
After 1.5 h of target cell control measurements, F5 MART1
reactive CTLs (Figure 2A–B) were added to the live cell imaging
chamber and imaged continuously for 18 h. This experiment
duration is similar to the time period typically required for
measurement of T cell activity by ELISPOT [3]. Single CTLs
killing individual target cells are identified through qualitative
analysis of the intensity image data as a change in appearance of
the target cell following prolonged contact with a CTL (Figure 3A–
Figure 2. Transduction of CD8+ enriched PBMCs. (A) Flow cytometry data of transduced T cells showing typical transduction efficiency of
donor PBMCs. (B) Flow cytometry of CD8+ enriched population showing CD8+ T-cell enrichment efficiency. (C) IFNg release assay validating F5-
transduced, CD8+ enriched T cell activation following co-culture with HLA-matched MART1 expressing M202 cells. Negative control M207 cells
express MART1, but are HLA-mismatched. (D) Mass vs. time of the healthy M202 cell shown in (E), demonstrating the viability of target cells on the
interferometer stage.
doi:10.1371/journal.pone.0068916.g002
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D). Cytotoxic events are detectable despite the presence of
nonspecific or unresponsive T cells within the broader population.
LCI provides quantitative maps of the mass distribution within
target cells during T cell mediated cytotoxic events (Figure 3E–H).
These mass distributions from successive image frames can be
integrated to yield measurements of target cell mass over time
(Equation 1 and Figure 3I). Individual cytotoxic events due to
recognition of CTLs are confirmed by a characteristic decrease in
target cell mass following prolonged contact (30 min to 2 h) with a
corresponding CTL (Figure 3I and Movie S1).
Target cell mass decreased by 20 to 60% over a period of 1–4 h
when successfully attacked by a CTL, as compared to an increase
in total target cell mass of 15% over 4 h when not killed by CTLs
(Figure 3I–J). Despite contact between T cells and target cells,
there was no response in control experiments using HLA
mismatched, antigen irrelevant target cells (lacking MART1) or
non-specific T cells (Figure 3 K–M, Figure S1C–D and Figur-
e S3C–D). This indicates that target cell death was due to the
presence of antigen-specific CTLs and that the rate and extent of
target cell mass decrease due to T cell mediated cytotoxicity is
directly quantifiable using LCI. T cell mediated cytotoxicity is
evident within the first 30 min and confirmed within the first 2–
4 h following the addition of CTLs, indicating the speed of the
LCI approach in measuring T cell mediated cytotoxicity
(Movie S1). An estimated 95% of target cells were dead by 18 h
after the addition of CTLs, while greater than 95% of control
target cells appeared healthy at 18 h (Figure 3 K–L and
Figure S3).
Figure 3. LCI tracks target cell death during T cell mediated cytotoxicity. (A–H) Images of a single cytotoxic event occurring immediately
after the start of imaging (t=0 is approximately 30 min after plating CTLs onto target cells), (A–D) intensity images at t= 0 and 5 h of imaging
demonstrating CTL mediated target cell killing. Yellow boxes in (A) and (C), indicate the subregion in images (B) and (D). Arrows in (B) and (D) indicate
the target cell tracked by mass profiling in (E–I). (E) LCI mass profile of selected target cell after initiation of persistent contact with a target cell at the
start of imaging. (F–H) LCI mass profile of dying target cell. (I) Measured total mass vs. time for target cell shown in (E–H). (J) Normalized mass of killed
and healthy target cells over time. Normalized mass is mass divided by initial mass. Healthy cells show roughly 15% increase in normalized mass over
4 h (blue line indicates mean of n= 311 healthy M202 cells, grey region indicates +/2 SD). Killed target cells (red lines) show a decrease in mass of 20
to 60% over 1–4 h. (K) intensity image of stage location shown in (A) and (C) after 18 h of imaging, showing nearly complete death of target cells. (L)
Intensity image of stage after 18 h of imaging M202 cells plated with untransduced (F5-) CD8+ T cells showing viability of target cells plated with
nonspecific T cells. (M) Normalized mass vs. time for n=2058 healthy M202 cells treated with untransduced, control CTLs, showing roughly 15%
increase in mass over 4 h.
doi:10.1371/journal.pone.0068916.g003
Mass Changes During CTL Target Cell Killing
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Mass increase of activated CTLs
In parallel with the decrease in target cell mass, individual
activated CTLs increased in overall size by the end of a cytotoxic
event (Figure 4). Individual CTL and target cell masses can be
tracked through the duration of their interactions (Figure 4A and
Figure S4). CTL mass versus time data for 10 such events is
summarized in Figure 4B, with CTL mass normalized relative to
the mass when the target cell dramatically changed morphology
(‘‘balled-up’’) at the start of a death event, which is defined as
t=0 h. In a typical trace, the target cell initially shows an increase
in mass consistent with the growth rate of a healthy cell
(Figure 3M). During this period (t,0 h), CTLs show a relatively
slow growth rate (Figure 4C). Then, the target cell ‘‘balls-up’’ and
detaches from the substrate, immediately prior to a very rapid loss
Figure 4. LCI measures CTL mass and mass accumulation rate during T cell mediated cytotoxicity. (A). Mass versus time of an activated
CTL and corresponding target cell. t= 0 h is the point at which the target cell detaches from the substrate at the beginning of cell death. CTL + target
cell refers to total mass of both cells in frames where they could not be measured separately. (B) Normalized mass versus time of 10 CTL-mediated
cytotoxicity events. CTL mass is normalized relative to the mass at the time of target cell morphology change, which is used as the t= 0 h point for all
traces. Gray lines show best fit lines used for determining mass accumulation rates. (C) Average mass accumulation rate of CTLs before a cytotoxic
event, during the first 100 min of a cytotoxic event, and after the first 100 min of a cytotoxic event demonstrating an approximately 4-fold increase in
mass accumulation during the first 100 min of a cytotoxic event. (D) LCI image of 9 unresponsive and 1 cytotoxic T cell illustrating an approximately
3-fold difference in mass. The white arrow indicates the activated T cell, as determined by tracking this cell after persistent contact with target cell
and subsequent target cell death. (E) The average mass of 116 activated CTLs is approximately 2.8-fold greater than the average mass of
unresponsive controls. (F) Average area of activated CTLs is only approximately 1.4-fold greater than non-activated controls and not significant at the
95% confidence level, illustrating the utility of LCI mass measurements for determining CTL activation. Error bars in C show 95% confidence intervals.
Error bars in E and F show +/2 SD. * p,0.05, ** p,0.01, *** p,1023. act = activated/cytotoxic, 116 cells, n= 3 experiments. unact = unactivated/
unresponsive, 359 cells, n= 3 experiments. F5- = untransduced, F5-negative control experiment, 530 cells, n=2 experiments. PC3 = PC3 cell, HLA-
mismatched irrelevant antigen control, 3015 cells, n= 3 experiments.
doi:10.1371/journal.pone.0068916.g004
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of mass over the first 1–2 hours. During this initial period
(approximately 100 min), the T cell mass accumulation rate
increases significantly (Figure 4C). As the target cell loses mass and
the central cell body condenses over the next 2–5 hours, the T cell
continues to increase in mass, at a slower rate than during the
initial period (Figure 4C).
This change in mass accumulation rate resulted in a significant
2 to 4-fold higher cellular mass than surrounding unresponsive T
cells (Figure 4D). The total cellular mass of 116 CTLs at the end-
point of each cytotoxic event was compared to the mass of 3,900
control T cells that did not kill targets during the course of the
experiment. On average, the CTLs had a 2.8-fold higher mass as
compared to their non-specific or unresponsive counterparts
(Figure 4E and Figure S5A). This mass increase persisted for up
to 4 h, a duration that is limited by the average period of
observation prior to the activated T cell being washed away due to
continuous media perfusion through the observation chamber.
The two-dimensional (2D) area of responsive versus unrespon-
sive T cells was calculated to determine whether there was a
significant difference relating to overall size. The observed 1.4-fold
increase in 2D area was smaller than the 2.8-fold difference in total
cell mass and did not achieve statistical significance at the p,0.05
level compared to controls (Figure 4F and Figure S5B). These
results show that the mass change of CD8+ T cells is a more robust
indicator for activity than the change in cell area. Additionally, for
spherical T cells, the observed 1.4-fold increase in mass
corresponds to a 1.7-fold increase in volume, which is substantially
lower than the observed 2.8-fold increase in mass. These results,
therefore, suggest that there is also an increase in T cell density
during activation, although density quantification is not possible
with the present configuration of LCI measurements.
Discussion
LCI provides a quantitative label-free cytotoxicity assay through
sensitive biomass measurements of single effector T cells and their
affected target cells during cytotoxic events (Figure 1). The mass of
killed target cells can be tracked over time to confirm a 20 to 60%
decrease in mass over 1 to 4 h, consistent with a cytotoxic insult
(Figure 3). We found a significant 4-fold increase in T cell mass
accumulation rate at the start of the cytotoxic event and a 2.8-fold
average increase in total mass of effector T cells after recognition
and killing of cognate target cells (Figure 4). The change of mass of
T cells was found to be a more significant indicator of T cell
activation state than measurements of 2D changes in area alone.
The mass increase we observed in activated CTLs is likely
accompanied by an increase in biosynthesis driven by metabolic
changes. It has been demonstrated that T cells use glucose and
glutamine as their primary energy sources. Activated lymphocytes
generate energy to meet protein synthesis demands by significantly
increasing glucose, amino acid and fatty acid uptake from the
extracellular environment [23]. Glucose deprivation studies have
shown that activated T cells require glucose for proliferation and
survival even in the presence of adequate levels of glutamine [24].
TCR signaling plays a critical role in regulating the transcription
of the glucose transporter Glut1, enabling enhanced glucose uptake
with activation [25]. Studies have shown that TCR agonists such
as anti-CD3 antibodies or compounds that cause cross-linking of
CD3 proteins result in a rapid and maximal induction of Glut1
expression [24,25].
A potential application of the LCI technique presented here is
for the identification and isolation of single and potentially rare
CTLs. A growing body of work has focused on the identification of
tumor infiltrating T lymphocytes (TILs) bearing TCR recognition
of autologous tumor cells [7,26]. Recent studies have indicated
that these CTLs occur at relatively low frequencies, making it
difficult to employ bulk or surrogate cytotoxicity assays to confirm
their existence and isolation from a mixed population [27,28]. The
LCI approach uses the cytotoxic interaction between CTLs and
target cells as a natural amplifier of the underlying peptide-MHC-
TCR recognition event which avoids false positives due to
nonspecific binding. The LCI imaging platform is fundamentally
compatible with a segmented culture system that will allow for
isolation of rare cells that may be lost in the current open perfusion
cell culture system. LCI may therefore provide a viable alternative
for the identification and isolation of rare effector T cells killing
autologous tumor cells or HLA-matched cancer cell lines.
T cells against cancer-associated antigens are generally antic-
ipated to bear lower affinity TCRs if they are raised against a self-
antigen and presumably escaped thymic selection and tolerance
induction [29]. The affinity between the TCR and peptide-MHC
is considered to play a crucial role in the outcome of T cell
stimulation [30]. The classic method to assess TCR-peptide-MHC
affinity entails the measurement of on and off-rates using surface
plasmon resonance. The surface bound peptide-MHC-TCR
interaction does not accurately mimic the multiple receptor-
mediated interactions that occur during recognition of a target cell
by a CTL. Evidence suggests that these measurements provide
limited information regarding lymphocyte effector function
[30,31]. In a transfection system, TCRs engineered with higher
affinity for cognate peptide-MHC ligands compared to their wild
type counterpart exhibited increased CTL activity [31]. An affinity
model suggests that activation of T cells is related to the number of
receptors engaged. Higher affinity interactions require less TCR-
peptide-MHC engagements to activate a T cell into a cytotoxic
state [32]. It is conceivable that higher affinity TCR-peptide-
MHC interactions drive a more rapid response than their lower
affinity counterparts, and the LCI approach may also potentially
discriminate between these interactions.
Supporting Information
Figure S1 Averaged, normalized mass versus time plots
for control target cell growth conditions showing robust
growth on the LCI stage, and specificity of T cell
mediated cytotoxicity. (A) Unaffected M202 cells (n=632)
during treatment with F5 TCR transduced, CD8+ T cells. (B)
M202 cells (n=117) prior to treatment with F5 TCR transduced,
CD8+ T cells. (C) M202 cells (n=2058) treated with F5 TCR
negative, CD8+ T cells. (D) Antigen-irrelevant, PC-3 prostate
cancer cells (n=1006) treated with F5 TCR transduced, CD8+ T
cells. Blue line shows mean normalized mass versus time
(normalized relative to mass at first timepoint). Light blue region
shows the mean +/2 SD.
(TIF)
Figure S2 Averaged, normalized mass versus time for
unresponsive T cells showing steady growth on the LCI
stage. (A) Unresponsive F5 TCR transduced CD8+ T cells
(n=101) plated with M202 target cells. (B) Untransduced CD8+ T
cells (n=146) plated with M202 target cells. (C) F5 TCR
transduced CD8+ T cells (n=950) plated with antigen-irrelevant,
PC-3 prostate cancer target cells.
(TIF)
Figure S3 Intensity images of cells on the interferom-
eter stage after 18 h of imaging showing typical target
cell conditons. Left column shows the full image frame, the right
column shows a subset of the full image frame. (A)–(D) M202
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target cells plated with F5 TCR transduced, CD8+ T cells showing
nearly complete death of target cells. For comparison, (A) and (B)
show the same field of view as in Fig. 2 A–F. (C), (D) show a single
living cell. E, F. M202 target cells plated with untransduced CD8+
T cells showing viability on the stage after 18 h of imaging and
cognate TCR requirement for T cell mediated cytotoxicity. (G),
(H). Antigen-irrelevant PC-3 prostate cancer target cells plated
with F5 TCR transduced CD8+ T cells showing the specificity of
the F5 TCR.
(TIF)
Figure S4 (A)–(J). Mass versus time plots for CTLs and
corresponding target cells, as in Figure 4A. t=0 h is the
point at which the target cell detaches from the substrate at the
beginning of cell death. CTL + target cell refers to total mass of
both cells in frames where they could not be measured
individually, typically due to overlap between the CTL and target
cell.
(TIF)
Figure S5 (A) Mass and (B) area histograms for
activated and unresponsive T cells, relative to control
experiments. Activated = activated/cytotoxic F5 TCR trans-
duced T cells, 116 cells, n=3 experiments. Unactivated =
unactivated/unresponsive F5 TCR transduced T cells, 359 cells,
n=3 experiments. F5neg = untransduced F5 TCR negative T
cells plated with M202 target cells, 530 T cells, n=2 experiments.
PC3 = F5 TCR transduced T cells plated with HLA-mismatched
antigen irrelevant PC-3 prostate cancer cells, 3015 T cells, n=3
experiments.
(TIF)
Movie S1 Four panel video showing intensity images,
mass distribution images, and mass vs. time of a target
M202 cell being killed by a cytotoxic T cell (CD8+, F5
TCR transduced) over the course of 5 hours of
observation by LCI.
(MOV)
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